Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs EB 001 (Primary)
- Indications Glabellar lines
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Bonti
- 09 Aug 2017 According to a Bonti media release, Dr. Steve Yoelin is one of the principal investigators.
- 09 Aug 2017 Results published in a Bonti Media Release.
- 03 May 2017 According to a Bonti media release, a total of 24 subjects in 4 cohorts have been treated to date (20 received active drug, 4 received placebo).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History